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Abstract
Current estimates suggest 50% of glaucoma blindness worldwide is caused by primary
angle-closure glaucoma (PACG) but the causative gene is not known. We used genetic link-
age and whole genome sequencing to identify Spermatogenesis Associated Protein 13,
SPATA13 (NM_001166271; NP_001159743, SPATA13 isoform I), also known as ASEF2
(Adenomatous polyposis coli-stimulated guanine nucleotide exchange factor 2), as the
causal gene for PACG in a large seven-generation white British family showing variable
expression and incomplete penetrance. The 9 bp deletion, c.1432_1440del; p.478_480del
was present in all affected individuals with angle-closure disease. We show ubiquitous
expression of this transcript in cell lines derived from human tissues and in iris, retina, retinal
pigment and ciliary epithelia, cornea and lens. We also identified eight additional mutations
in SPATA13 in a cohort of 189 unrelated PACS/PAC/PACG samples. This gene encodes a
1277 residue protein which localises to the nucleus with partial co-localisation with nuclear
speckles. In cells undergoing mitosis SPATA13 isoform I becomes part of the kinetochore
complex co-localising with two kinetochore markers, polo like kinase 1 (PLK-1) and centro-
some-associated protein E (CENP-E). The 9 bp deletion reported in this study increases the
RAC1-dependent guanine nucleotide exchange factors (GEF) activity. The increase in GEF
activity was also observed in three other variants identified in this study. Taken together, our
data suggest that SPATA13 is involved in the regulation of mitosis and the mutations
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dysregulate GEF activity affecting homeostasis in tissues where it is highly expressed, influ-
encing PACG pathogenesis.
Author summary
Glaucoma is the leading cause of irreversible blindness globally. Angle closure glaucoma
accounts for 50% of all glaucoma blindness impacting quality of life and burden on health
services. A number of variations in DNA appear to influence the risk of the disease. How-
ever, the biological mechanism underlying this important disease remains unclear. In this
paper, we report the identification and functional characterisation of the first gene, muta-
tion in which causes primary angle closure glaucoma in a seven generation Caucasian
family. We have identified other variants in the same gene in another family and individu-
als with the disease. This gene is involved in cell division and is highly expressed in parts
of the eye affected by the disease. Mutations in this gene appear to affect important
enzyme activity involved in cell division. Identification of the disease-causing role of
mutations in this gene helps to further the understanding of glaucoma aetiology and iden-
tifies potential therapeutic targets for disease management.
Introduction
Glaucoma is the most common cause of irreversible blindness worldwide, affecting nearly 80
million people [1]. It is characterised by an intermittently progressive optic neuropathy, often
culminating in loss of vision if left untreated [2]. Two main subtypes are primary open angle
glaucoma (POAG) [3] and primary angle closure glaucoma (PACG)[2]. PACG accounts for a
quarter of all glaucoma, but causes half of all glaucoma blindness [4]. Physical obstruction of
the aqueous humor outflow channels and consequent elevation of pressure inside the eye, are
hallmarks of this disease. Typically PACG occurs in eyes that are smaller than average. [5].
Two PACG loci are recognized—GLC2A in a Singaporean family on 10q identified by
genetic linkage analysis [6] and another locus mapped to the 3q27.1 region [7] using a popula-
tion-based GWAS study in Singaporean Malay, Indian and Beijing Chinese populations. How-
ever, no causative gene has been identified for PACG at these loci. Vithana and co-workers
found a genome-wide significant association between PACG and three loci: rs11024102 in
pleckstrin homology domain containing family A member 7 (PLEKHA7) on chromosome
11p, rs3753841 in COL11A1on chromosome 1p, and rs1015213 located between PCMTD1 and
ST18 on chromosome 8q in a mixture of Far East, Middle East, Indian and UK populations [8,
9]. The two single nucleotide polymorphisms (SNPs) in PLEKHA7 and COL11A1 were repli-
cated in a large PACG cohort in China [10], Australia and Nepal [11]. Variants in PLEKHA7,
an adherens junction protein, increase the risk of sudden, symptomatic pressure rises in
PACG [10]. This protein is expressed in iris, ciliary body, and choroid [12] and has GTPase-
activating protein (GAP) activity [13]. SNPs in other candidate genes, including HGF (hepato-
cyte growth factor) [14], HSP70 (heat-shock protein 70) [15], MFRP (membrane type frizzled
related protein) [16], eNOS (endothelial nitric oxide synthase) [15] and MMP9 (matrix metal-
loproteinase-9) [17] also have significant association with PACG.
Next generation sequencing has renewed interest in using family data to identify causal
gene(s) for otherwise complex disorders. It exploits information about co-segregation, thus
helping to identify potentially causal variants. Rare variants of large effect influencing the sus-
ceptibility to the disease are present at a higher frequency in affected than in unaffected
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individuals in families, as well as the general population. Using this strategy, we have identified
SPATA13 as the causative gene for PACG in a large multigenerational Caucasian family and
shown that this protein is likely to influence tissue homeostasis.
Results
Pedigree recruitment
A seven-generation Caucasian British family (Family 1) was recruited at Moorfields Eye Hos-
pital (MEH). The proband V:8 (Fig 1; red arrow) attended with her sister V:15 and daughter
Fig 1. Pedigree of Family 1. The proband is V:8 (red arrow) and this pedigree shows the relationship of the 62
individuals examined (see S1 Table for detailed phenotype). There was no male-to-male transmission observed, and
the only affected male was V:30, a first cousin of the proband. From branch B, two out of nine individuals examined
were affected. There were no individuals examined from branches A and C affected with angle-closure disease. Twelve
subjects, four of whom were affected first cousins, were genotyped for genetic linkage analysis, and some were analysed
in greater detail by exome and whole genome sequencing. It is suspected that the phenotype in VII:2 and VI:7 is caused
by another genetic defect as it is very likely that their disease is inherited from the married in spouse (V:11).
https://doi.org/10.1371/journal.pgen.1008721.g001
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VI:4. They gave a strong family history of glaucoma (S1 Table). Proband V:8 had been treated
for ocular hypertension for 15 years from age 52. On examination all three, V:8, V:15 and VI:4,
were found to have the same phenotype of plateau iris configuration (PIC, Fig 2A). The pro-
band’s mother IV:11 underwent surgery for PACG. Including her mother, the proband had
nine other aunts and uncles, i.e. ten siblings in generation IV who lived to adulthood, consist-
ing of seven sisters and three brothers. Establishing a detailed pedigree enabled us to expand
the family tree to seven generations and contact 63 members. Twelve of these (including V:11,
unrelated, spouse) had occluded drainage angles (primary angle-closure suspect—PACS),
PAC (Primary angle-closure disease) or PACG (see S1 Text). The family had lived in the East
London area since at least 1812.
Linkage analysis
All family members with occluded drainage angles or PACG were selected for linkage analysis
(see S1 and S2 Text). An autosomal dominant disease transmission was observed in Family 1,
with more affected females than males. This may be attributable due to the majority of the off-
spring of III:11 being female (seven daughters and three sons in adulthood; five out of seven
daughters in generation IV were affected) but could also reflect the greater predisposition of
women because of their smaller eyes. Individual VI:7 was not included in this analysis as her
mother, V:11, not related to this family and married-in spouse of V:10, is affected. For similar
reasons, her daughter (VII:2) was also not included as there could be another gene responsible
for the disease, which could come through V:11. Eleven samples from this family (IV:32,
IV:27, V:8, V:14, V:15,V:28, V:30, V:32, V:34, V:41, VI:4 highlighted in yellow in Fig 1) were
genotyped on the Human CytoSNP-12 (298,199 markers) on the Illumina platform. Superlink
Online SNPv1.1 was used to investigate genetic linkage in this family assuming a disease allele
frequency of 1%.
An affected-only multipoint linkage analysis was performed using IV:27, V:8, V:15, V:30,
V:32, V:34, V:41, VI:4 (S2 Table). After removal of uninformative markers, highest positive
LOD score was observed on chromosome 13 between rs9580111 and rs1160226 (Max LOD
Score 2.90, NPL Spair 3.80, NPL ALL 18.7). LOD scores above 1 were also observed on chro-
mosome 5 between rs1478449—rs3812042 (Max LOD score 1.25, NPL Spair 1.44, NPL ALL-
0.75), chromosome 9 between rs10979427- rs419097 (Max LOD score 1.72, NPL Spair 1.47,
NPL ALL 1.76). On chromosome 13 these values increased to Max LOD score 3.5, NPL Spair
4.7, NPL ALL 34.5 when the unaffected individual IV:32, who at 94 years of age did not show
any signs of PACG, was included (allowing for 90% penetrance in the parametric model) (Fig
2B). Including another unaffected subject V:28 also gave similar results (Max LOD score
3.760913, NPL-Spair 4.81, NPL ALL 37.12). A proximal crossover at rs10400673 and
rs2166431 at the distal end in individual V:8 narrowed the genetic interval to 4.1 Mbp.
Whole exome and genome sequencing
Four “clearly affected” members of this family, V:8, V:30, V:32 and VI:12 were analysed further
with exome sequencing using SureSelect Target Enrichment System, followed by sequencing
on a HiSeq2000 (Illumina) with 100bp paired end reads. The average ratio of reads alignment
to reference genome was 71%. When measured at a minimum depth of 20x, 93% of the
intended targets were covered. Initial filtration of variants (total number of variants in 4 sam-
ples was 98,808) was performed to identify heterozygous variants (60,329) shared between the
four affected individuals (reduced to the total number to 4,836 variants, i.e. 1,209 candidate
variants per sample), followed by selecting all the shared variants with MAF of<0.01. Only
one variant, SPATA13 (NM_001166271, chromosome 13q) c.1432_1440del; p.478_480del
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Fig 2. Clinical features and linkage analysis of Family 1. (A) Plateau iris configuration was observed for all nine clearly affected individuals V:8, V:15, VI:4, V:32,
V:30, IV:27, VI:12 and V:34, V:41) on gonioscopy. In the first two columns, closed anterior chamber drainage angles are observed. The middle column shows high
resolution AS-OCT angle imaging, where the bulky ciliary body typical of plateau iris is observed. Individual IV:27 is the oldest and most severely affected PACG
individual, showing some additional iris convexity. Individuals V:28, VI:36 and VI:6 have open drainage angles and are shown for comparison. (B) Maximum
multipoint LOD score of 3.5 achieved at chromosome 13 by Superlink-Online SNP-1.1. (C) Pedigree of the family 5 identified with the 9 bp deletion. The proband,
5.II.2, shown by an arrowhead carry the deletion. His mother, 5.I.2 was affected but no DNA was available for analysis. Proband has an affected daughter, 5.III.2,
but her eye phenotype is different to his. Her mother, 5:II.3, has narrow but open angles and was hyperopic and it is therefore suspected that the daughter has
inherited her disease from the mother.
https://doi.org/10.1371/journal.pgen.1008721.g002
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fulfilled the filtering criteria. On Sanger sequencing it was found that this variant segregated in
all the nine clearly affected samples. The variant was absent in 11 of the 16 blood-related, unaf-
fected family members and none of the spouses carried the variant. Results from five of the
unaffected subjects were inconclusive due to poor quality of DNA. Two subjects with uncer-
tain diagnosis and three subjects with other ocular conditions also carried this change. (S1
Table).
The 9 bp in-frame deletion in SPATA13 results in deletion of three amino acids, QSP.
There are three repeats of QSP within this region; the mutation deleted one of them. This vari-
ant had a MAF of 0.0001158 in Kavier, 0.0006118 in gnomAD Exomes, and 0.0008671 in gno-
mAD genomes. We also analysed V:15, V:30, IV:27 and V:28 by whole genome sequencing on
HiSeqX with 30x coverage as some genes showed poor coverage on WES within the linked
region on chromosome 13. The variants in the affected (V:15, V:30, IV:27) were compared
with the unaffected V:28. The only variant with an allele frequency of less than 0.01 that was
shared in all affected individuals within the linked regions was SPATA13 (NM_001166271)
c.1432_1440del; p.478_480del.
Prevalence of SPATA13 mutations in unrelated patient cohort
To identify additional variants in SPATA13, all 13 coding exons were screened by Sanger
sequencing in a cohort of 189 unrelated patients: PACS (n = 14)/PAC (n = 106, 52 acute) and
PACG (n = 69, 3 acute). One patient, (5:II:2, Fig 2C, S3 Table) with PACS carried the same 9
bp SPATA13 deletion (c.1432_1440del; p.478_480del) identified in Family 1 (S3 Table). Geno-
type analysis of SNPs within SPATA13 and its adjacent region show that this individual was
not related to Family 1. The genotypes and segregation of this mutation in this family and the
clinical details are given in S3 Text.
We also identified another eight variants in SPATA13 amongst eight unrelated patients
(Table 1, Fig 3A), seven of them were in exon 2, the largest in this gene. In our cohort the
prevalence of individuals with a rare SPATA13 variant was 4.8%. The MAF of all variants were
less than 0.002 in gnomAD, 1000Genomes and EXAC databases. There are two variants that
were identified in two subjects of African ancestry, the rest were present in Caucasian subjects.
One variant, p.R89P, is present in 1% of the African population, the other variant, p.S246T,
was present in 1000 Genomes with a frequency of 0.00019. We did not screen a control African
DNA panel as it was not available to us. The rest of the variants in SPATA13 were screened in
a control cohort of 192 random European Caucasians. In this control cohort all the 13 exons
Table 1. List of variants identified in SPATA13 in a cohort of 189 PAC/PACG patients.
patient ID Location CDS position Protein position SIFT PolyPhen CADD score gnomAD Allele Frequency
6:I 13:24223195–24223195 c.G266C p.R89P deleterious Probably
damaging
26.5 0.001335
7:I 13:24223426–24223426 c.C497T p.P166L tolerated benign 9.475 0.001762
8:I 13:24223666–24223666 c.G737C p.S246T tolerated benign 12.47 0.0000381
4:I 13:24223804–24223804 c.G875T p.S292I tolerated possibly
damaging
22.3 0.00000661
10:I 13:24224016–24224016 c.C1087T p.R363C deleterious Possibly
damaging
25.5 0.0002
9:I 13:24224083–24224083 c.C1154T p.A385V tolerated benign 15.17 0.00115
2:II:I 13:24224347–24224347 c.G1418A p.S473N deleterious Possibly
damaging
22.4 0.000824
3:I 13:24290695–24290695 c.C2891T p.P964L tolerated Probably
damaging
24.9 0.0000244
https://doi.org/10.1371/journal.pgen.1008721.t001
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of SPATA13 were screened by Sanger sequencing where we identified one subject carrying the
c.C497T, p.P166L variant. This variant also had a CADD value lower than 10 so presumably
this was a rare polymorphism. This shows that the rare variants identified in this study are sig-
nificantly enriched in our PAC/PACG cohort (S4 Text).
The degree of conservation of all the variants in SPATA13 identified in this study is shown
for all nine species (Fig 3B). The predicted secondary structure of SPATA13 shows that the
first 800 residues at the N-terminus, where most of the variants are located, has higher percent-
age of random coil compared with the C-terminus (Fig 3C). The 9 base pair deletion makes
the N terminus of SPATA13 more compact when compared with the wildtype protein (com-
pare Fig 3D with 3E).
Fig 3. Location and predicted effect of mutations in SPATA13 gene on protein conformation. (A) Structure of SPATA13 gene structure and location of 8 mutations
in exon 2 and the 9th mutation in exon 9. (B) Conservation of amino acids mutated in PACG in 9 different species. (C) Secondary structure prediction for the amino
acid sequence of SPATA13 polypeptide. (D) Predicted tertiary structure of SP-1277 containing the 9bp (p. 478-480del) deletion. (E) Wildtype SP-1277 showing the
location of all the missense variants.
https://doi.org/10.1371/journal.pgen.1008721.g003
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Expression of SPATA13 transcripts in human cell lines and eye tissues
Multiple SPATA13 transcripts differing in their 5’ region have been reported and designated
ASEF2a-d [18]. One of the short transcripts, ASEF2b (NM_153023), encoding a 652 amino
acid protein (NP_694568), has been studied in detail [19–21]. This transcript also contains one
of the nine mutations reported above. For simplicity, we will refer NP_001159743 as SP-1277
and NP_694568 as SP-652 based on the amino acid number they encode. We investigated the
expression levels of these two SPATA13 transcripts by qPCR. Transcript specific primers were
designed to detect NM_153023 (encoding SP-652) and NM_001166271 (encoding SP-1277) as
well as total SPATA13 as shown in Fig 4A. Seventeen different human cell lines derived from
the eye (retinal pigment epithelial, RPE-1), liver (HepG2), kidney (HEK293), cervix (HeLa),
oesophagus (TR146), fibrosarcoma (HT1080), breast (SUM159, T47D), skin (N/Tert-1,
HaCaT), head and neck cancers (HN4, HN8, SCC4, SCC9), oral dysplasia (SVpgC2a), and
those produced from SVpgC2a by nicotine treatment (SVFN3 and SVFN10) [22] were ana-
lysed. As shown in Fig 4B, these transcripts were detected in all 17 cell lines. The transcripts
for SP-1277 showed highest expression in RPE-1, SVFN3 and low in SCC9 whereas the tran-
script for SP-652 was highest in N/Tert-1, SCC4 and lowest in SCC9 (Fig 4B). These results
suggest that the two transcripts are ubiquitously expressed at varying levels in multiple cell
lines derived from different human tissues.
We also used qPCR to investigate the mRNA expression of SP-1277 and SP-652 in human
iris, ciliary epithelium, retinal pigmented epithelium (RPE), retina, cornea and the lens (Fig
4C). The transcripts for SP-652 showed highest expression in cornea and lens, whereas the
transcripts for SP-1277 was highest in cornea and ciliary epithelium, suggesting that SP-1277
was the predominant transcript in tissues most affected in PAC/PACG.
SPATA13 antibodies characterisation and expression in the eye
There are several commercially available antibodies which recognise SP-1277 and SP-652. To
confirm their specificities, we cloned SP-1277, SP-652 isoforms and the first N-terminal 625
residues of SP-1277 (SP-1277-N625) (Fig 5A) as AcGFP fusion proteins and expressed them in
HT1080 cells. Protein bands of around 166kDa (SP-1277), 100kDa (SP-652 and SP-1277-N625)
were detected with anti-AcGFP antibody (Fig 5B). In this study we have used four different
antibodies, two against the N- and two against the C-terminal of SP-1277 (available from
Abcam and ThermoFisher Scientific). The N-terminal antibodies recognised SP-1277 but
showed no reactivity with SP-652 (representative blots of Abcam antibodies are shown in Fig
5B). As shown in Fig 5C, the Abcam C-terminal antibody recognised a band of 70kDa and
several high molecular weight bands in the range of 80-180kDa (Fig 5C, lane 1). The N-termi-
nal antibody from ThermoFisher reacted with several high molecular weight bands in the
range of 80-180kDa (Fig 5C, lane 2) while the Abcam antibody recognised a single band of
180kDa (Fig 5C, lane 3) but did not bind to the 70kDa band showing the specificity of these
reagents. To further test the specificity of the antibody on tissue culture cells, RPE-1 cells were
transfected with AcGFP tagged SP-1277 (AcGFP-SP-1277) and immunostained with the N-
terminal SPATA13 antibody. As shown in Fig 5D there was complete co-localisation of the
AcGFP-SP-1277 with the N-terminal antibody. Similar results were obtained when the C-ter-
minal SPATA13 antibody was used to identify the AcGFP-SP-1277. These results show that
the N and C-terminal SPATA13 antibodies were able to recognise SP-1277 in western blots
and immunostaining. In this study, the two N-terminal SPATA13 antibodies were used inter-
changeably, however, the data presented here are mostly with the Abcam antibody.
To investigate whether SP-1277 protein is expressed in the eye we used the N-terminus
antibody on murine (Fig 5E & 5F) and human (Fig 5G) eye sections using
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Fig 4. Expression of different SPATA13 transcripts in human cell lines and eye tissues. (A) Schematic
representation of the transcripts of different isoforms of SPATA13. The two isoform SP-1277 and SP-652 isoforms are
generated by alternative splicing of exons toward the N-terminal. The position of qPCR primers used to differentiate
the 2 transcripts are also shown. (B) Expression of SPATA13 transcripts by qPCR in 17 different cell lines derived from
human eye, breast, liver, skin, head and neck, cervix and kidney. (C) Expression of SP-1277 and SP-652 transcripts in
human iris, ciliary epithelium, retinal pigment epithelium, retina, cornea and lens. The green bars represent
SPATA13-Total whereas the blue bars represent SP-1277 and the red bars represent SP-652.
https://doi.org/10.1371/journal.pgen.1008721.g004
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immunohistochemistry. As shown in Fig 5E–5G, we observed specific reactivity with both pig-
mented and non-pigmented ciliary epithelia, iris sphincter and dilator muscles, corneal epithe-
lium and retinal outer nuclear, inner nuclear and ganglion cell layers.
SPATA13 shows nuclear and cytoplasmic localisation in RPE-1 cells
Having established expression of SPATA13 in the eye, we investigated the cellular localisation
of the endogenous SP-1277 isoform using the antibodies characterised in Fig 5. With the N-
terminus antibody, a predominantly grainy nuclear staining was observed in RPE-1 cells (Fig
6A). The C-terminus antibody, which should recognise all the SPATA13 isoforms, also gave
almost identical staining (Fig 6B). Similar observations have been reported on HeLa cells
using SPATA13 antibodies [23]. As SP-652 has been implicated in actin function [23], we
investigated the co-localisation of SPATA13 with F-actin in RPE-1 cells. Fig 6A and 6B show
that both the N- and C-terminal antibodies gave reactivity in the nucleus as well as in the cyto-
plasm with little co-localisation with F-actin. We also observed no co-localisation of SPATA13
staining with nuclear actin (Fig 6C).
To investigate the functions of each isoform individually, we transfected AcGFP-SP-1277
and its N-terminus 625 residues (AcGFP-SP-1277-N625) in RPE-1 cells. AcGFP-SP-1277 was
primarily localised as globules in the nucleus with some cytoplasmic staining (Fig 6D), which
could be due to a single 14 residues bipartite nuclear localisation signal (NLS)
574-RTPKRRWGSGRRPR-587 identified by NLStradamus [24] (Fig 5A). When AcGFP-SP-
1277-N625 was ectopically expressed in RPE-1 cells, it gave homogenous nuclear AcGFP
expression (Fig 6E). Four of the nine variants (S292I, S473N, 478-480d and P964L) reported
here were introduced by site-directed mutagenesis and expressed in RPE-1 cells. The nuclear
localisation of these variants did not change when compared with the wildtype suggesting the
mutations do not affect localisation. (S1 Fig).
Role of SP-1277 in mitosis
While investigating the cellular expression of SPATA13 isoforms, we observed that some cells
undergoing cell division showed very speckled localisation of SP-1277 in the equatorial region
of the dividing cells. To investigate this further, we examined the localisation of SP-1277 in
RPE-1 cells at different stages of cell division (Fig 7). SP-1277 showed granular nuclear signal
at interphase with a faint background cytoplasmic signal which remained visible throughout
mitosis (Fig 7A). Cells were co-stained with acetylated α-tubulin, to mark the microtubules,
centrosomes and spindles. At the beginning of prophase, SP-1277 coalesced into intense
speckles within the nucleus, which condensed further and moved towards the equatorial
region during metaphase. At anaphase, SP-1277 speckles localised specifically along the
Fig 5. Characterisation of SP-1277 isoform. (A) Schematic representation of the domain structure of SP-1277
isoform. Light blue bar shows the epitope for the N-terminal antibodies and the red bar shows epitope for the C-
terminal antibodies. The nuclear localisation signal in the terminal region SP-1277N625is shown by a hashed blue bar.
The boundary of SP-1277-N625 and SP-652 are shown two discontinuous lines. The SH3, DBL homology (DH) and PH
domains are shown in SP-652. (B) Western blot analysis of the SPATA13 and its fragments analysed by N-terminus
(ab122627) and anti-AcGFP antibodies. AcGFP fusion protein of SP-1277, SP-1277-N625 and the SP-652 were
expressed in HT1080 cells, total cell lysate was separated on 4–15% SDS polyacrylamide gel, transferred on
nitrocellulose membrane and probed with different antibodies. Specific reactivity with protein bands is shown by
asterisks. (C) Western blot of total RPE-1 lysate probed with the C-terminus (lane 1) and N-terminal (lane 2,
ThermoFisher; lane 3, Abcam) antibodies. (D) Reactivity of N- and C-terminal antibodies with RPE-1 cells
overexpressing SP-1277 compared with AcGFP control. Immuohistochemical reactivity of murine eye tissues (E, F)
and human eye tissues (G) with the N-terminus antibody from Abcam (ab122627). CE = ciliary epithelium,
CP = ciliary process, PP = pars plana, GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer,
SM = sphincter muscle, DM = dilator muscle, PE = posterior muscle. Re = retina, Co = cornea, Le = lens.
https://doi.org/10.1371/journal.pgen.1008721.g005
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kinetochore. The SP-1277 signal dispersed as the daughter cells separated, with only a faint
background signal remaining.
To investigate this novel observation, we examined whether SP-1277 was colocalising with
the kinetochore. We co-stained RPE-1 cells for SP-1277 and two kinetochore markers, polo-
Fig 6. Endogenous and ectopic expression of SPATA13 isoforms. Human RPE-1 cells were immunostained with SP-
1277 (N-terminus antibody, A) and SP-652 (C-terminus antibody, B) and co-stained for endogenous F-actin (Alexa
Fluor 594 conjugated phalloidin). (C) To detect nuclear actin, RPE-1 cells were transfected with nuclear actin
chromobody (nAC) probe construct [55] and were counterstained with N-terminal specific SP-1277 antibody. RPE-1
cells were transiently transfected with AcGFP-tagged SP-1277 (D), and SP-1277-N625(E) respectively, both
counterstained for F-actin. AcGFP-SP-1277 localised to nuclear speckles with a diffuse but variable cytoplasmic signal
(S), AcGFP-SPATA13-N625 (E) only showed nuclear staining. Nuclei were stained with DAPI (blue). Scale
bar = 10 μM.
https://doi.org/10.1371/journal.pgen.1008721.g006
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Fig 7. Endogenous SP-1277 isoform during mitosis. Endogenous SP-1277 protein was localised in dividing RPE-1 cells, during mitosis using the N-terminus antibody
and counterstained using anti-acetylated α-tubulin antibody (A), or counter stained with two mitotic markers PLK-1 (B) and CENP-E (C). (A) SP-1277 was detected in
the nucleus as speckles at G0, which intensified at the onset of prophase, aligning along the kinetochore at metaphase, and anaphase, before returning to its G0 localisation
pattern. (B) SP-1277 globules show co-localisation with the kinetochore marker PLK-1 at prophase, metaphase and anaphase. At cytokinesis the PLK-1 staining is
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like kinase 1 (PLK-1) and centrosome associated protein E (CENP-E). As shown in Fig 7B,
SP-1277 starts to co-localise with PLK-1 at the beginning of prophase and remains co-localised
along the kinetochore complex in pro-metaphase and metaphase. At cytokinesis SP-1277 dis-
tributes in the cytoplasm with strong staining at the midbody. Similar colocalisation of SP-
1277 was observed with CENP-E (Fig 7C). To quantify the degree of colocalisation we selected
RPE-1 at two different stages of mitosis, prophase (Fig 8A) and anaphase (Fig 8F). Visual
methods (described in S5 Text) indicated colocalisation of SP-1277 (green) and CENP-E (red)
at prophase as shown in Fig 8A and in Fig 8B and 8C. We also observed that the colocalisation
showed strong linear distribution in the scatterplots (Fig 8D and 8E). Automatic thresholding
algorithm of Costes [25] showed localisation of CENP-E was 84% with SP-1277 and 75% of
SP1277 localised with CENP-E. Similar results were obtained with ImageJ colocalisation plu-
gins and the image analysis software package Imaris (Fig 8D & 8E). At anaphase SP-1277 and
CENP-E showed 84% colocalisation (Fig 8F), with more colocalisation at the kinetochores of
the separating chromosome and very little at the metaphase plate.
Influence of mutations on the GEF activity of SP-1277
As SP-652 has been shown to have GEF activity, we investigated if additional 625 residues at
the N-terminus of SP-652 would affect this activity. GEF activity was measured by co-trans-
fecting AcGFP-SP-1277 (wildtype or mutants) and RAC-1 in RPE-1 cells (Fig 9). In these
experiments, SP-652 lacking the first 204 residues (SP-652del204) was used as positive control
as it has been shown that removing 204 residues from the N-terminus increases its GEF activ-
ity [26]. There was a 1.5 fold increase in GEF activity of SP-652 compared with RAC-1 only,
which increased to 2.5 fold when the first 204 residues were deleted.
SP-1277 had lower GEF activity than SP-652 (Fig 9) suggesting the random coil region in
SP-1277 had a negative impact on its GEF activity. We also investigated whether the 9 bp dele-
tion affected the GEF activity of SP-1277. There was more than 2 fold increase in GEF activity
due to the 9 bp deletion. We further investigated the GEF activity in another three of the nine
variants (S292I, S473N, P964L). The highest change was observed in S473N and P964L. The
activity of SP-652 containing P964L mutation was also increased by about 2.5 fold suggesting
that this mutation clearly affected the GEF activity.
Discussion
Pathogenesis of angle closure glaucoma is complex with multiple heritable factors affecting the
disease progression and severity. Singling out individual factors contributing to the disease is
crucial for unravelling the pathway leading to the development of PACG. The lack of suitably
large families with multiple affected individuals, together with disease heterogeneity, has ham-
pered classical genetic linkage analyses and positional mapping studies of PACG. However,
recent advances in medical imaging techniques, such as anterior segment optical coherence
tomography (AS-OCT) have improved phenotypic classification of the angle-closure disease.
We used this technique to supplement clinical examination of the relationship between the
angle and iris and lens.
In this study, we have used detailed phenotyping in combination with linkage analysis of
the largest reported PACG family and next generation sequencing to identify SPATA13/
ASEF2 as a gene that harbors a disease-causing mutation leading to PACG. In this family
primarily localized at midbody between the dividing cell which also co-stains for SP-1277. (C) SP-1277 show strong co-localisation with another kinetochore marker
CENP-E at prophase, prometaphase and anaphase. At anaphase the colocalization primarily is around the separated chromosomes. Nuclei were stained using DAPI (blue).
https://doi.org/10.1371/journal.pgen.1008721.g007
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PACG was associated with a 9 bp deletion in SPATA13 showing variable expression and
reduced penetrance (S6 Text). There were 39 blood related subjects that were clinically exam-
ined and genotyped, of these 5 were unaffected, giving us a reduced penetrance of 87.2%.
However, of the 5 unaffected, 2 males, VI:25 (42y) and VI:26 (48y), may develop PAC/PACG
later, so excluding them from the analysis would increase the penetrance to 92.3%. There is a
possibility, although very small, that there might be another variant deep in the intron or in
another gene in linkage disequilibrium with SPATA13 as the filtration of variants were priori-
tised for coding regions. However, we identified additional 8 individuals with rare variants in
Fig 8. Colocalization analysis of SP-1277 with CENP-E at prometaphase and anaphase. (A) At prometaphase SP-1277 (green) co-localises with
CENPE-E (red) globules. To evaluate whether colocalization occurs, a line was drawn connecting different globules (B). The green and red intensity was
measured using ImageJ in globules along the line and plotted (C). The data was analysed using Image J and Imaris softwares and showed colocalization of
84% (tM0.84) of CENP-E with SP-1277 and 75% (tM = 0.75) of SP-1277 with CENP-E. Fluorescence intensity data of two images were distributed linearly
as shown in the scatterplots (Fig 8D & 8E). The colocalization of SP-1277 with CENP-E in anaphase is shown in (F). The regions of interest showing
highest colocalization are labelled as 1 and 2. The degree of colocalization of the two molecules was analysed using ImageJ (1a, and 1b for region 1) and (2a
and 2b for region 2) and gave a colocalization of more than 80%.
https://doi.org/10.1371/journal.pgen.1008721.g008
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SPATA13, one of whom carried the same 9 bp deletion, strengthening the genetic evidence
(Table 1). Analysis of SNPs within SPATA13 showed that the second proband with the 9 bp
deletion is not related to Family 1. In this family the penetrance appears to be low, but we
believe that the phenotype of the daughter is inherited from her mother, giving a penetrance of
100%. This is explained in detail in S3 Text.
Further evidence for the involvement of SPATA13 in PACG comes from the protein
expression data shown in Fig 5. This is the first study where SP-1277 expression is shown in
iris, cornea, ciliary epithelium and retina of the human and murine eyes, the tissues most
affected in PACG.
A number of GWAS studies have implicated SP-1277 in several neurological disorders
including intellectual disability [27], comorbid depression syndrome and alcohol dependence
[28] and anorexia nervosa in human [29] and social hierarchy and nocturnal activity in mice
[30]. It has also been implicated in differentiated thyroid cancer risk [31] and BRCA1-like
early onset breast cancer [32]. The SPATA13 gene product has never been implicated in any
eye disease, this is the first study implicating this protein in PACG. The gene produces several
transcripts, here we have shown that two SPATA13 transcripts are ubiquitously present in cell
lines derived from different human tissues as well as in the eye tissues including cornea, iris,
retina, RPE and the lens. This raises an interesting question; if SPATA13 is a ubiquitously
Fig 9. SPATA13 mutations induced GEF activity in SP-1277. (A) RPE-1 cells were co-transfected with Flag-RAC-1
along with wildtype SP-1277, wildtype SP-652 or mutants (S292I, S473N, 478-480d, P964L) cloned in
pLPCpuro_NAcGFP and after lysis the GTP-RAC-1 was immunoprecipitated with PAK-PBD beads and analysed on
western blot using anti-Flag antibody. (B) Quantification of GEF activity of SP-1277 (wildtype and mutants). One way
ANOVA was used to test the null hypothesis of no difference between GEF activity in mutants and wildtype, with there
being a significant difference (p = 0.002).
https://doi.org/10.1371/journal.pgen.1008721.g009
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expressed protein, why do mutations in this gene only affect the eye? The obvious possibility is
that the mutations do cause pathogenesis in other tissues, but they have not been diagnosed or
investigated. It is also conceivable that in other organs the effect of mutations is overcome by
tissue-specific expression of other proteins. However, there are reports where mutations in a
ubiquitously expressed protein only affects the eye, e.g., mutations in PRPF31 only cause reti-
nitis pigmentosa and does not affect any other part of the body [33].
The SP-652 isoform has been reported to regulate cellular events such as reorganisation of
cytoskeletal structures, cell migration [23] and angiogenesis [34, 35]. The other isoform SP-
1277 which has an additional 625 residues at the N-terminus due to alternative splicing of SP-
652, has never been investigated and its function is not known. SP-652 contains an adenoma-
tous polyposis coli (APC)-binding region (ABR) followed by a Src homology 3 (SH3) domain,
a Dbl homology (DH) domain and a Pleckstrin (PH) domain (Fig 5A), which is also present in
SP-1277. The ABR-SH3 domain binds to APC, which activates its GEF activity to mediate
downstream cellular events [18]. At the protein level we show that endogenous SP-1277 local-
ises to both nucleus and cytoplasm in interphase, which is consistent with previous reports for
endogenous SP-652 expression [36]. In silico 3-D structural prediction analysis showed that
SP-1277 contains 16 intrinsically disordered regions (IDR) (Fig 3C), the longest of which is
157 residues. It has been reported that SP-652 is normally in an inactive conformation until
the Armadillo (ARM) domain of APC binds to the ABR and SH3 domain and facilitate the
Cdc42 exchange [26]. It is likely that post translational modification or binding of APC to the
ABR-SH3 domain of SP-1277 releases the DH domain activating its GEF activity and that the
IDR acquires a tertiary structure creating binding sites for other proteins and/or DNA/RNA
for its additional downstream functions. SP-652 lacks this IDR and therefore binding of APC
will result in downstream functions different to SP-1277. The 9 bp deletion (p.478_480del) is
predicted to make the IDRs more compact (compare Fig 3D with 3E), which would likely
affect their interactions with binding proteins including APC.
In this study we have shown dramatic redistribution of SP-1277 during different stages of
cell division suggesting a role in mitosis. Although there are fundamental anatomical and
structural differences between the mouse and human eyes, such as lack of a lamina cribrosa or
a macula, which may lead to different neurodegenerative pathways, two independent studies
have shown that complete knockout of all SPATA13 isoforms in mouse was not embryonic
lethal and had no ocular phenotype [30, 34]. This suggests that SPATA13 was not essential for
mitosis, but instead may have a regulatory role. Similar results have been reported with myoci-
lin (MYOC), a gene associated with POAG pathogenesis [37]. Heterozygous and homozygous
mice lacking myocilin show no ocular phenotype, however, missense mutations in this protein
are not tolerated and lead to POAG [38].
Rho GTPases are involved in major cellular functions including cell growth, adhesion,
motility, polarity and differentiation by controlling different cellular processes such as cyto-
skeletal remodeling, microtubule dynamics, gene transcription and phospholipid metabolism.
Rho signaling responses in cells are highly regulated spatiotemporally to ensure homeostasis
within the cell. They switch between active GTP bound and inactive GDP bound states with
the help of RHO-GEFs, RHO-GAPs and RHO-guanine nucleotide dissociation inhibitors
(RHO-GDIs). The localised modulation of Rho GTPases by GEFs, GAPs and GDIs depends
on cell type and presents a complex network of highly integrated regulatory mechanisms. Rho
GTPases are also key components of neuronal cell degeneration pathways [39]. The Rho
GTPase signaling pathway has been shown to modulate aqueous humour outflow by regulat-
ing the contractile properties of trabecular meshwork and Schlemm’s canal cells in humans
[40, 41]. Inactivation of Rho GTPases significantly stimulated/increased adult ciliary epithelial
cell proliferation in situ [42]. One of the key features of RHO-GEFs and RHO-GAPs is that
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their activities are autoinhibited and are sensitive to local activation. SP-652 has been shown to
be inactive for RHO-GEF and is activated by binding to APC. In this report we only investi-
gated 4 of the 8 SPATA13 variants for their effect on GEF activity. We have shown that SP-
1277 exhibits less GEF activity than SP-652 and the 9bp deletion increases the RAC1-depen-
dent GEF activity. This has also been observed for three additional variants identified in
SPATA13 (Fig 9), which suggested that conformational changes introduced by mutations in
these variants affect the function through altering the GEF activity. It is likely that the rest of
the variants that have not been tested might behave differently and may not show any differ-
ence in their GEF activity. It should be noted that PLEKHA7, another protein implicated in
PACG (19), has GAP activity and therefore could interact with RAC1 similar to SP-1277. It is,
therefore, also likely that both SP-1277 and PLEKHA7 are involved in Rho-GTPase pathway,
indicating this pathway could play an important role in PACG disease pathogenesis.
It is important to note that a proportion of SP-1277 is always in the cytoplasm even in divid-
ing cells suggesting that it can also play a role in cell adhesion and migration. The mutations
reported here enhance GEF activity of SP-1277, which could dysregulate mitosis with impact
on symmetric/asymmetric cell division, cell adhesion and migration as has been reported for
SP-652 [19, 21, 23, 43, 44]. Dysfunction in cell adhesion has been identified as a genetically
modulated risk factor in PACG (14–19) and is likely to cause its effect through degradation of
the blood aqueous barrier. PLEKHA7 encodes an apical junctional protein that is expressed in
the non-pigmented ciliary epithelium, a key component of the blood aqueous barrier (BAB).
Lee et al found that PLEKHA7 is down regulated in the iris of PACG patients that carry the C
risk allele at SNP 11024102[13]. Silencing of PLEKHA7 in non-pigmented ciliary epithelium
(NPCE) affected actin cytoskeleton organization in vitro. Consistent with the regulatory role of
RAC-1 and Cdc42 in maintaining tight junction permeability, silencing of PLEKHA7 compro-
mises the paracellular barrier between NPCE cells in vitro. The authors concluded that down-
regulation of PLEKHA7 in PACG may affect BAB integrity [13].
Other evidence supporting the involvement of SPATA13 in PACG comes from our expression
studies where it is highly expressed in iris, cornea, ciliary body and retina (Fig 5C–5F), the tissue
most affected by the disease. The malformation of the ciliary epithelium would also impact aque-
ous humour secretion as well as attachment of lens zonules which would affect the positioning of
the lens as observed in PACG [45]. Disturbances in tissue homeostasis of the uvea may increase
the propensity for shedding of pigment from the pigmented ciliary or iris epithelia. We observed
increased trabecular meshwork pigmentation in all patients carrying the 9 bp deletion, except the
youngest two males aged 24y and 26y, in whom disease signs might develop later.
APC and the kinetochore associated proteins have been investigated as targets for develop-
ing therapeutics for cancer treatment [46]. APC, which interacts with the two close homo-
logues, ASEF1 and ASEF2 (41), is a peptidomimetic target for colon cancer treatment [47].
Cell cycle inhibitors are being investigated in targeting preferentially aneuploid cancer cells
while sparing normal diploid cells. Similar strategies may offer the prospect of treatment for
PACG involving APC-SPATA13/ASEF2 interactions.
In conclusion, we have identified SPATA13 as a gene in which mutations cause primary
angle-closure disease, which in turn puts those affected at risk of developing glaucomatous loss
of vision. There is variable expression and incomplete penetrance of the phenotype associated
with this gene. Detailed functional characterisation of SP-1277 and mutations identified in this
study will provide insights into the mechanism of disease pathogenesis, strengthening the
hypothesis that abnormalities in cell division and/or cell adhesion in the anterior segment of
the eye might be a common mechanism in the development of PACG. Identification of
SPATA13 as one of the disease-causing genes for PACG opens new avenues for identifying
additional genes in this pathway causing PACG.
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Methods and materials
Informed, written consent was obtained from all participants. This study followed the princi-
ples of the Declaration of Helsinki. The study was approved by the Moorfields NHS Research
Ethics Committee (06/Q0504/8).
Family history and pedigree recruitment. The index patient for each family (proband),
underwent pedigree charting, enquiring about a family history of glaucoma and/or angle-clo-
sure. The accuracy of family history information was confirmed by corroboration of relatives
attending the clinics. All family members of the proband, aged 20 years and older were invited
to attend ophthalmic examinations. The Society of Genealogists (http://www.sog.org.uk/)
helped identify distant relatives using publicly available genealogy and census data. A family
member from of the five largest families sent letters of invitation explaining the research to
their distant relatives, inviting them to participate.
Clinical examination. Detail clinical examination procedure and diagnostic classification
is given in S2 Text. Each participant examined in research clinics underwent comprehensive
ophthalmic examination including dark room gonioscopy, visual field testing as well as a clini-
cal examination of the optic disc, and supplementary imaging of the optic disc and peripapillary
retina. The primary defining feature of cases was contact between the iris and trabecular mesh-
work identified on dark room gonioscopy and/or anterior segment imaging. Primary angle-clo-
sure glaucoma was diagnosed when there was evidence of iridotrabecular contact and
glaucomatous damage to the optic nerve, as detailed under the ISGEO diagnostic standards [2].
DNA isolation and Sanger sequencing. DNA was extracted from peripheral blood using
Gentra PureGene kit (Qiagen, UK). Sanger sequencing was performed with BigDyev3.1 (Life
Technologies) on ABI3730 according to manufacturer’s protocol. 192 human random control
DNAs were purchased from Merk.
SNP chip array and linkage analysis. Single nucleotide polymorphism (SNP) genotyping
was undertaken on 11 individuals from Family I. Processing of SNP microarrays (Illumina,
Human CytoSNP-12, 298,199 markers) was performed according to the manufacturer’s proto-
col. The relationship status of participants was checked against their genotype using the GRR
software (http://csg.sph.umich.edu/abecasis/grr/) to identify errors in pedigree charting and
possible non-paternity. Overall call rates were>98% for all samples and no gender mismatch
was found. The marker sets were reduced to the 3,547 most informative markers distributed
uniformly throughout the chromosomes to avoid artificially inflating LOD scores due to link-
age disequilibrium between closely spaced SNPs. All genotype calls were checked for Mende-
lian inconsistencies and two-point and multipoint linkage analyses of genome wide SNP data
were performed using Superlink-Online SNP-1.1 [48] using an autosomal dominant model,
100% penetrance in the affected-only analysis, 90% penetrance in other analyses.
Exome and whole genome sequencing. Genomic DNA from the proband of family I was
fragmented enriched for exomic sequences using the Agilent SureSelect Whole Exome hybrid
capture (Agilent, UK). The resulting enriched sequence library was sequenced with 76bp
paired end reads across two lanes of Illumina GAIIx flowcell (v2 chemistry). The sequence
reads were aligned to the reference genome (hg18) with the Novoalign aligner. Duplicate
reads, resulting from PCR clonality or optical duplicates, and reads mapping to multiple loca-
tions were excluded from downstream analysis. Single nucleotide substitutions and small
insertion/deletions were identified, and quality filtered within the SamTools software package.
Whole genome sequencing was performed on HiSeqX with 30x coverage at Edinburgh
Genomic Centre, UK. The sequence reads were aligned to hg19 and the data was obtained as
BAM and VCF files. VCFTools were used to filter the variants within the genetically linked
region. Pathogenicity of the variants were evaluated by VEF (Ensemble) and CADD.
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Antibodies. Two SPATA13 antibodies, SP-1277 (ab122627) and SP-652 (ab122701) were
purchased from Abcam (UK), PA5-59479, PA5-59096 from Thermofisher antibodies, PLK-1
(ab17057) and CENP-E (ab5093) from Abcam. Mouse monoclonal alpha-tubulin antibody
(ab7291), were purchased from Abcam (UK). Alexa Fluor 488-conjugated goat anti-mouse
(A11001) and anti-rabbit (A11008) antibodies, Alexa Fluor 594-conjugated goat anti-mouse
(A11005) and anti-rabbit (A11034) antibodies, and donkey anti-goat antibodies conjugated
with Alexa Fluor 488 (A11055) and with Alexa Fluor 594 (A11058), were purchased from Life
Technologies (CA, USA). Alexa Fluor 594 labelled Phalloidin was purchased from Life Tech-
nologies (CA, USA). Horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse IgG
were purchased from Jackson Immuno Research Laboratories, Inc. (PA, USA).
Molecular cloning and mutagenesis. Total mRNA was isolated from cultured cells using
the Dynabeads mRNA DIRECT Purification Kit (Ambion, Paisley, UK) using manufacturer’s
instructions and transcribed into cDNA using the Transcriptor Reverse Transcriptase System
(Roche, Burgess Hill, UK). The coding regions of SP-652 and SP-1277 were amplified using
high fidelity Q5 DNA polymerase (New England Biolabs, UK) and ligated into
pLPC_NAcGFP using standard cloning techniques [49]. The retroviral expression vector
pLPC_NMyc (gift from Professor Titia de Lange (Addgene plasmid #12540) was re-engineered
to replace N-Myc tag with AcGFP. For site-directed mutagenesis phosphorylated primers har-
bouring the desired mutations were used to amplify the SPATA13 constructs with Q5 DNA
polymerase and ligated with Taq DNA ligase. Sanger sequencing was used to verify all cloned
inserts and mutations.
SDS electrophoresis and western blotting. SDS electrophoresis and western blotting
were performed according to protocol described previously [50].
mRNA extraction, cDNA synthesis and quantitative PCR. Total RNAs from pooled
human eye tissues, ciliary body, iris, retinal epithelium and retina were commercially obtained
from 3H Biomedical AB (Sweden) and isolated from cornea and lens tissues using RNeasy
Mini Kit (Qiagen) as per manufacturer’s instructions. The RNA samples were reverse tran-
scribed into cDNAs as described above. Specific primers for three different forms of SPATA13
(NM_001286792; NM_001166271 and NM_153023; were designed spanning exon-exon junc-
tions with Tm of forward and reverse primers within ±1˚C. NM_001286792; F: AAGGACCC
TCTGAGGACGTAG; R: ACAGGTCACCCCTAGCTGG, NM_001166271; F: ACGCTGAC
TTTGTAGGCTCC; R: TCATCTCCAGGAATGCCGTC, NM_153023; F: GACACGCTGAC
TTTGTAGGC; R: ATCCTGTGATGAGCTTCGCC, SPATA13_Total; F: GCTCAAAAGG
CAGGACATGG; R: CATAGTGATGTGGCGCTGGT. Quantitative PCR (qPCR) was per-
formed on the LightCycler 480 qPCR System (Roche, UK) according to protocol described by
Bose et al. [51]. The qPCR analyses for mRNA expression in cell lines were performed in three
independent replicates, with three technical repeats for every sample. However, for human eye
tissues the expression was performed only in three technical replicates.
Mammalian Cell Culture and Immunocytochemistry. Human (h)TERT-RPE-1 retinal
pigment epithelial cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM)/
F-12+GlutaMAX (Life Technologies, CA, USA) supplemented with 10% FCS and penicillin–
streptomycin (100 μg/ml). All cells were grown in 6-well plates at 1.2 x106 cells per well at
37˚C in an atmosphere of 5% CO2.
Prior to immunofluorescence (IF) studies, cells were seeded in 24-well plates on glass cover-
slips at 5.0 x 104 cells per well and incubated for 24 h. The cells were processed for immunocy-
tochemistry as described previously [50].
Transfections were performed in semi-confluent hTERT-RPE1 or HT1080 cells using the
TransIT-LT1 Transfection Reagent (Mirus Bio LLC, USA), according to the manufacturer’s
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instructions. The cells were fixed 24 h post transfection prior to IF staining as described above.
Retroviral packaging and transduction was carried as described previously [50]
Imaging and image processing. Confocal images were obtained on Zeiss LSM880 with a
63x/1.4NA oil objective. Quantitation of colocolisation is described in S5 Text.
GEF activity measurement. RPE-1 cells were co-transfected with wildtype SP-1277 or
mutants (S292I, S473N, 478-480del, P964L) or wildtype SP-652 or SP-652(P964L) or SP-
652del204 cloned in pLPCpuro_NAcGFP along with Flag-RAC-1 using TransIT-LT1 Trans-
fection Reagent (Mirus Bio LLC, USA), according to the manufacturer’s instructions. After 24
h the transfected cells were starved in 0.5% serum for 4 h. The cells were lysed, GTP-RAC-1
was pulled down using PAK-PBD beads (Cytoskeleton incorporation, USA) and analysed on
4–15% gradient gel followed by western blot using anti-Flag antibody. The blots were analysed
and quantified by ChemiDoc using Image Lab software from Bio-Rad.
Immunohistochemistry. Formalin fixed paraffin embedded human eye tissues and
murine eye were cut into 5μm sections, dewaxed using xylene and immunostained using SP-
1277 N-terminus specific antibody as described previously [52, 53].
3D structure prediction. I-TASSER was used for prediction of secondary and tertiary
structure of SPATA13 [54].
Statistical analysis: Gene expression data were exported from Roche LightCycler LC480
Software as text files for subsequent analysis. Statistical analysis for qPCR and GEF assays were
carried out by the t-test on Graph Pad Prism software and Microsoft Excel.
URLs used in the study. http://www.ensembl.org/index.html
http://csg.sph.umich.edu/abecasis/grr/
http://cbl-hap.cs.technion.ac.il/superlink-snp/
https://zhanglab.ccmb.med.umich.edu/I-TASSER/
http://cadd.gs.washington.edu/
http://www.sog.org.uk/
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(TIF)
S1 Table. Detailed clinical information of members in Family 1.
(XLSX)
S2 Table. Genotypes of eight affected and two unaffected subjects of Family 1.
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S3 Table. Detailed clinical information of 8 additional PAC/PACG patients and their rela-
tives carrying mutations in SPATA13.
(XLSX)
Acknowledgments
Authors would like to thank the patients and their families for their enthusiastic support, Bev-
erley Scott for excellent technical assistance, Quincy Prescott for help with linkage analysis,
Hemanth Tummala for help in protein modelling, Usman Baig for help with the figures and
Diana Swinfield for family tracing. We also acknowledge contributions from Catherine Grigg,
Carolyn Ford, Satareh Shekouhi, Sofia Fernandes, Sheetal Patel, Jessica Brennan, Janet Miller,
Lily Weerasuriya, Dominic Carrington, Gayna Winzar-Mills, Ee Lin Ong, Kristie Fan, Mat-
thew Richardson, Leonieke Van Koolwijk, Niall Mullally, Diana Bouglas, Tuan Ho, Min-
gguang He, Kay-Tee Khaw, Nick Wareham, Shabina Hayat, Robert Luben, Wendy Franks,
Maria Papadopoulos, Winnie Nolan, Gus Gazzard, Jonathan Clarke, Saurabh Goyal, Darren
Behn, Avi Kulkarni, Conrad Yuen, Roger Hitchings, Alison Hardcastle, Andrew McNaught,
Andrew Webster, Alice Davidson, Graeme Black and Michael Cheetam. The authors would
like to thank Andrew Yeudall (Augusta, Georgia, USA) for HN4 and HN8, and Teck Teh for
SVFN3 and SVFN10 cell lines.
Author Contributions
Conceptualization: Naushin H. Waseem, Sancy Low, Peng T. Khaw, Shomi S. Bhattacharya,
Ahmad Waseem, Paul J. Foster.
Data curation: Naushin H. Waseem, Amna Z. Shah, Pia Ostergaard, Michael Simpson, Belen
Martin-Martin, Ege Sackey, Ahmad Waseem, Paul J. Foster.
Formal analysis: Naushin H. Waseem, Michael Simpson, Ege Sackey, Shomi S. Bhattacharya,
Ahmad Waseem, Paul J. Foster.
Funding acquisition: Naushin H. Waseem, Sancy Low, Shomi S. Bhattacharya, Paul J. Foster.
Investigation: Naushin H. Waseem, Sancy Low, Amna Z. Shah, Deepa Avisetti, Pia Oster-
gaard, Katarzyna A. Niemiec, Belen Martin-Martin, Hebah Aldehlawi, Saima Usman, Pak
Sang Lee, Jonathan B. Ruddle, Ameet Shah, Alexander Day, Yuzhen Jiang, Geoff Swinfield,
Ananth Viswanathan, Giovanna Alfano, Christina Chakarova, Heather J. Cordell, David F.
Garway-Heath, Peng T. Khaw, Shomi S. Bhattacharya, Ahmad Waseem, Paul J. Foster.
Methodology: Naushin H. Waseem, Sancy Low, Deepa Avisetti, Katarzyna A. Niemiec, Hebah
Aldehlawi, Saima Usman, Giovanna Alfano, Heather J. Cordell, Shomi S. Bhattacharya,
Ahmad Waseem, Paul J. Foster.
Project administration: Naushin H. Waseem, Shomi S. Bhattacharya, Ahmad Waseem, Paul
J. Foster.
PLOS GENETICS Primary angle closure glaucoma and SPATA13
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008721 April 27, 2020 22 / 26
Resources: Sancy Low, Pak Sang Lee.
Supervision: Shomi S. Bhattacharya, Ahmad Waseem, Paul J. Foster.
Validation: Naushin H. Waseem, Belen Martin-Martin, Ahmad Waseem, Paul J. Foster.
Visualization: Amna Z. Shah.
Writing – original draft: Naushin H. Waseem, Sancy Low, Ahmad Waseem, Paul J. Foster.
Writing – review & editing: Naushin H. Waseem, Sancy Low, Amna Z. Shah, Deepa Avisetti,
Pia Ostergaard, Michael Simpson, Anthony P. Khawaja, Shomi S. Bhattacharya, Ahmad
Waseem, Paul J. Foster.
References
1. Quigley HA. Angle-closure glaucoma-simpler answers to complex mechanisms: LXVI Edward Jackson
Memorial Lecture. Am J Ophthalmol. 2009; 148(5):657–69 e1. Epub 2009/11/03. https://doi.org/10.
1016/j.ajo.2009.08.009 PMID: 19878757.
2. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prev-
alence surveys. Br J Ophthalmol. 2002; 86(2):238–42. Epub 2002/01/30. https://doi.org/10.1136/bjo.
86.2.238 PMID: 11815354; PMCID: PMC1771026.
3. Weinreb RN, Khaw PT. Primary open-angle glaucoma. The Lancet. 2004; 363(9422):1711–20. https://
doi.org/10.1016/s0140-6736(04)16257-0
4. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J
Ophthalmol. 2006; 90(3):262–7. Epub 2006/02/21. https://doi.org/10.1136/bjo.2005.081224 PMID:
16488940; PMCID: PMC1856963.
5. Alsbirk PH. Anterior chamber depth, genes and environment. A population study among long-term
Greenland Eskimo immigrants in Copenhagen. Acta Ophthalmol (Copenh). 1982; 60(2):223–4. Epub
1982/04/01. https://doi.org/10.1111/j.1755-3768.1982.tb08376.x PMID: 7136533.
6. Aung T, Bowman R, Chew PT, Seah SK, Ang LP, Yap E, et al. Genome-wide linkage scan for primary
angle closure glaucoma. Investgative Ophthalmology & Visual Science. 2003; 44:3224.
7. Vithana EN, Khor CC, Cornes BK, Nongpiur ME, Jonas JB, Saw SM, et al., editors. Association Analy-
sis Identifies a Susceptibility Locus on Chromosome 3q27 for Primary Angle Closure Glaucoma. Investi-
gative Ophthalmology & Visual Science; 2012. ARVO Annual Meeting Abstract.
8. Vithana EN, Khor CC, Qiao C, Nongpiur ME, George R, Chen LJ, et al. Genome-wide association anal-
yses identify three new susceptibility loci for primary angle closure glaucoma. Nat Genet. 2012; 44
(10):1142–6. Epub 2012/08/28. https://doi.org/10.1038/ng.2390 PMID: 22922875; PMCID:
PMC4333205.
9. Khor CC, Do T, Jia H, Nakano M, George R, Abu-Amero K, et al. Genome-wide association study identi-
fies five new susceptibility loci for primary angle closure glaucoma. Nat Genet. 2016; 48(5):556–62.
Epub 2016/04/12. https://doi.org/10.1038/ng.3540 PMID: 27064256.
10. Chen Y, Chen X, Wang L, Hughes G, Qian S, Sun X. Extended association study of PLEKHA7 and
COL11A1 with primary angle closure glaucoma in a Han Chinese population. Invest Ophthalmol Vis
Sci. 2014; 55(6):3797–802. Epub 2014/05/24. https://doi.org/10.1167/iovs.14-14370 PMID: 24854855.
11. Awadalla MS, Thapa SS, Hewitt AW, Burdon KP, Craig JE. Association of genetic variants with primary
angle closure glaucoma in two different populations. PLoS One. 2013; 8(6):e67903. Epub 2013/07/11.
https://doi.org/10.1371/journal.pone.0067903 PMID: 23840785; PMCID: PMC3695871.
12. Lee MC, Chan AS, Goh SR, Hilmy MH, Nongpiur ME, Hong W, et al. Expression of the primary angle
closure glaucoma (PACG) susceptibility gene PLEKHA7 in endothelial and epithelial cell junctions in
the eye. Invest Ophthalmol Vis Sci. 2014; 55(6):3833–41. Epub 2014/05/08. https://doi.org/10.1167/
iovs.14-14145 PMID: 24801512.
13. Lee MC, Shei W, Chan AS, Chua BT, Goh SR, Chong YF, et al. Primary angle closure glaucoma
(PACG) susceptibility gene PLEKHA7 encodes a novel Rac1/Cdc42 GAP that modulates cell migration
and blood-aqueous barrier function. Hum Mol Genet. 2017; 26(20):4011–27. Epub 2017/10/11. https://
doi.org/10.1093/hmg/ddx292 PMID: 29016860.
14. Awadalla MS, Thapa SS, Burdon KP, Hewitt AW, Craig JE. The association of hepatocyte growth factor
(HGF) gene with primary angle closure glaucoma in the Nepalese population. Mol Vis. 2011; 17:2248–
54. Epub 2011/09/08. PMID: 21897747; PMCID: PMC3164689.
PLOS GENETICS Primary angle closure glaucoma and SPATA13
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008721 April 27, 2020 23 / 26
15. Ayub H, Khan MI, Micheal S, Akhtar F, Ajmal M, Shafique S, et al. Association of eNOS and HSP70
gene polymorphisms with glaucoma in Pakistani cohorts. Mol Vis. 2010; 16:18–25. Epub 2010/01/14.
PMID: 20069064; PMCID: PMC2805420.
16. Wang IJ, Lin S, Chiang TH, Chen ZTY, Lin LLK, Hung PT, et al. The association of membrane frizzled-
related protein (MFRP) gene with acute angle-closure glaucoma–a pilot study. Mol Vis. 2008; 14:1673–
9. PMCID: PMC2532703. PMID: 18781223
17. Chen X, Chen Y, Wiggs JL, Pasquale LR, Sun X, Fan BJ. Association of Matrix Metalloproteinase-9
(MMP9) Variants with Primary Angle Closure and Primary Angle Closure Glaucoma. PLoS One. 2016;
11(6):e0157093. Epub 2016/06/09. https://doi.org/10.1371/journal.pone.0157093 PMID: 27272641;
PMCID: PMC4896618.
18. Kawasaki Y, Sagara M, Shibata Y, Shirouzu M, Yokoyama S, Akiyama T. Identification and characteri-
zation of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42. Oncogene. 2007;
26(55):7620–27. Epub 2007/06/30. https://doi.org/10.1038/sj.onc.1210574 PMID: 17599059.
19. Bristow JM, Sellers MH, Majumdar D, Anderson B, Hu L, Webb DJ. The Rho-family GEF Asef2 acti-
vates Rac to modulate adhesion and actin dynamics and thereby regulate cell migration. J Cell Sci.
2009; 122(Pt 24):4535–46. Epub 2009/11/26. https://doi.org/10.1242/jcs.053728 PMID: 19934221;
PMCID: PMC2787464.
20. Jean L, Majumdar D, Shi M, Hinkle LE, Diggins NL, Ao M, et al. Activation of Rac by Asef2 promotes
myosin II-dependent contractility to inhibit cell migration on type I collagen. J Cell Sci. 2013; 126(Pt
24):5585–97. Epub 2013/10/23. https://doi.org/10.1242/jcs.131060 PMID: 24144700; PMCID:
PMC3860307.
21. Evans JC, Hines KM, Forsythe JG, Erdogan B, Shi M, Hill S, et al. Phosphorylation of serine 106 in
Asef2 regulates cell migration and adhesion turnover. J Proteome Res. 2014; 13(7):3303–13. Epub
2014/05/31. https://doi.org/10.1021/pr5001384 PMID: 24874604; PMCID: PMC4084842.
22. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, et al. FOXM1 upregulation is an early
event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transforma-
tion. PLoS One. 2009; 4(3):e4849. Epub 2009/03/17. https://doi.org/10.1371/journal.pone.0004849
PMID: 19287496; PMCID: PMC2654098.
23. Sagara M, Kawasaki Y, Iemura SI, Natsume T, Takai Y, Akiyama T. Asef2 and Neurabin2 cooperatively
regulate actin cytoskeletal organization and are involved in HGF-induced cell migration. Oncogene.
2009; 28(10):1357–65. Epub 2009/01/20. https://doi.org/10.1038/onc.2008.478 PMID: 19151759.
24. Nguyen Ba AN, Pogoutse A, Provart N, Moses AM. NLStradamus: a simple Hidden Markov Model for
nuclear localization signal prediction. BMC Bioinformatics. 2009; 10:202. Epub 2009/07/01. https://doi.
org/10.1186/1471-2105-10-202 PMID: 19563654; PMCID: PMC2711084.
25. Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S. Automatic and quantitative mea-
surement of protein-protein colocalization in live cells. Biophys J. 2004; 86(6):3993–4003. Epub 2004/
06/11. https://doi.org/10.1529/biophysj.103.038422 PMID: 15189895; PMCID: PMC1304300.
26. Hamann MJ, Lubking CM, Luchini DN, Billadeau DD. Asef2 functions as a Cdc42 exchange factor and
is stimulated by the release of an autoinhibitory module from a concealed C-terminal activation element.
Mol Cell Biol. 2007; 27(4):1380–93. Epub 2006/12/06. https://doi.org/10.1128/MCB.01608-06 PMID:
17145773; PMCID: PMC1800726.
27. Harripaul R, Vasli N, Mikhailov A, Rafiq MA, Mittal K, Windpassinger C, et al. Mapping autosomal reces-
sive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate
genes in 192 consanguineous families. Mol Psychiatry. 2018; 23(4):973–84. Epub 2017/04/12. https://
doi.org/10.1038/mp.2017.60 PMID: 28397838.
28. Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V, et al. Genome-wide associa-
tion study of comorbid depressive syndrome and alcohol dependence. Psychiatr Genet. 2012; 22
(1):31–41. Epub 2011/11/09. https://doi.org/10.1097/YPG.0b013e32834acd07 PMID: 22064162;
PMCID: PMC3241912.
29. Boraska V, Franklin CS, Floyd JA, Thornton LM, Huckins LM, Southam L, et al. A genome-wide associ-
ation study of anorexia nervosa. Mol Psychiatry. 2014; 19(10):1085–94. Epub 2014/02/12. https://doi.
org/10.1038/mp.2013.187 PMID: 24514567; PMCID: PMC4325090.
30. Bourbia N, Chandler P, Codner G, Banks G, Nolan PM. The guanine nucleotide exchange factor,
Spata13, influences social behaviour and nocturnal activity. Mamm Genome. 2019; 30(3–4):54–62.
Epub 2019/04/26. https://doi.org/10.1007/s00335-019-09800-9 PMID: 31020388.
31. Figlioli G, Kohler A, Chen B, Elisei R, Romei C, Cipollini M, et al. Novel genome-wide association study-
based candidate loci for differentiated thyroid cancer risk. J Clin Endocrinol Metab. 2014; 99(10):
E2084–92. Epub 2014/07/17. https://doi.org/10.1210/jc.2014-1734 PMID: 25029422.
32. Scott CM, Wong EM, Joo JE, Dugue PA, Jung CH, O’Callaghan N, et al. Genome-wide DNA methyla-
tion assessment of ’BRCA1-like’ early-onset breast cancer: Data from the Australian Breast Cancer
PLOS GENETICS Primary angle closure glaucoma and SPATA13
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008721 April 27, 2020 24 / 26
Family Registry. Exp Mol Pathol. 2018; 105(3):404–10. Epub 2018/11/14. https://doi.org/10.1016/j.
yexmp.2018.11.006 PMID: 30423315; PMCID: PMC6289279.
33. Vithana EN, Abu-Safieh L, Allen MJ, Carey A, Papaioannou M, Chakarova C, et al. A human homolog
of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chro-
mosome 19q13.4 (RP11). Mol Cell. 2001; 8(2):375–81. Epub 2001/09/08. https://doi.org/10.1016/
s1097-2765(01)00305-7 PMID: 11545739.
34. Kawasaki Y, Tsuji S, Muroya K, Furukawa S, Shibata Y, Okuno M, et al. The adenomatous polyposis
coli-associated exchange factors Asef and Asef2 are required for adenoma formation in Apc(Min/+)
mice. EMBO Rep. 2009; 10(12):1355–62. Epub 2009/11/07. https://doi.org/10.1038/embor.2009.233
PMID: 19893577; PMCID: PMC2799213.
35. Kawasaki Y, Jigami T, Furukawa S, Sagara M, Echizen K, Shibata Y, et al. The adenomatous polyposis
coli-associated guanine nucleotide exchange factor Asef is involved in angiogenesis. J Biol Chem.
2010; 285(2):1199–207. Epub 2009/11/10. https://doi.org/10.1074/jbc.M109.040691 PMID: 19897489;
PMCID: PMC2801248.
36. Kawasaki Y, Tsuji S, Sagara M, Echizen K, Shibata Y, Akiyama T. Adenomatous polyposis coli and
Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. J Biol Chem.
2009; 284(33):22436–43. Epub 2009/06/16. https://doi.org/10.1074/jbc.M109.020768 PMID:
19525225; PMCID: PMC2755965.
37. Kim BS, Savinova OV, Reedy MV, Martin J, Lun Y, Gan L, et al. Targeted Disruption of the Myocilin
Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function. Mol Cell Biol.
2001; 21(22):7707–13. Epub 2001/10/18. https://doi.org/10.1128/MCB.21.22.7707-7713.2001 PMID:
11604506; PMCID: PMC99941.
38. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, et al. Identification of a gene
that causes primary open angle glaucoma. Science. 1997; 275(5300):668–70. Epub 1997/01/31.
https://doi.org/10.1126/science.275.5300.668 PMID: 9005853.
39. DeGeer J, Lamarche-Vane N. Rho GTPases in neurodegeneration diseases. Exp Cell Res. 2013; 319
(15):2384–94. Epub 2013/07/09. https://doi.org/10.1016/j.yexcr.2013.06.016 PMID: 23830879.
40. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res.
2013; 37:1–12. Epub 2013/06/19. https://doi.org/10.1016/j.preteyeres.2013.05.002 PMID: 23770081.
41. Epstein DL, Rowlette LL, Roberts BC. Acto-myosin drug effects and aqueous outflow function. Invest
Ophthalmol Vis Sci. 1999; 40(1):74–81. Epub 1999/01/15. PMID: 9888429.
42. Del Debbio CB, Santos MF, Yan CY, Ahmad I, Hamassaki DE. Rho GTPases control ciliary epithelium
cells proliferation and progenitor profile induction in vivo. Invest Ophthalmol Vis Sci. 2014; 55(4):2631–
41. Epub 2014/04/03. https://doi.org/10.1167/iovs.13-13162 PMID: 24692128.
43. Toriyama M, Mizuno N, Fukami T, Iguchi T, Toriyama M, Tago K, et al. Phosphorylation of doublecortin
by protein kinase A orchestrates microtubule and actin dynamics to promote neuronal progenitor cell
migration. J Biol Chem. 2012; 287(16):12691–702. Epub 2012/03/01. https://doi.org/10.1074/jbc.M111.
316307 PMID: 22367209; PMCID: PMC3339951.
44. Jean L, Yang L, Majumdar D, Gao Y, Shi M, Brewer BM, et al. The Rho family GEF Asef2 regulates cell
migration in three dimensional (3D) collagen matrices through myosin II. Cell Adh Migr. 2014; 8(5):460–
7. Epub 2014/12/18. https://doi.org/10.4161/19336918.2014.983778 PMID: 25517435; PMCID:
PMC4594452.
45. Friedman DS, Gazzard G, Foster P, Devereux J, Broman A, Quigley H, et al. Ultrasonographic biomi-
croscopy, Scheimpflug photography, and novel provocative tests in contralateral eyes of Chinese
patients initially seen with acute angle closure. Arch Ophthalmol. 2003; 121(5):633–42. Epub 2003/05/
14. https://doi.org/10.1001/archopht.121.5.633 PMID: 12742840.
46. Kawakami M, Liu X, Dmitrovsky E. New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy.
Annu Rev Pharmacol Toxicol. 2019; 59:361–77. Epub 2018/08/16. https://doi.org/10.1146/annurev-
pharmtox-010818-021649 PMID: 30110577.
47. Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, et al. Peptidomimetic inhibitors of APC-Asef interac-
tion block colorectal cancer migration. Nat Chem Biol. 2017; 13(9):994–1001. Epub 2017/08/02. https://
doi.org/10.1038/nchembio.2442 PMID: 28759015.
48. Silberstein M, Weissbrod O, Otten L, Tzemach A, Anisenia A, Shtark O, et al. A system for exact and
approximate genetic linkage analysis of SNP data in large pedigrees. Bioinformatics. 2013; 29(2):197–
205. Epub 2012/11/20. https://doi.org/10.1093/bioinformatics/bts658 PMID: 23162081; PMCID:
PMC3546794.
49. Sambrook JF, Russell DW. Molecular Cloning: A Laboratory Manual, 3rd ed.: Cold Spring Harbor Labo-
ratory Press; 2001.
50. Aldehlawi H, Niemiec KA, Avisetti DR, Lalli A, Teh MT, Waseem A. The monoclonal antibody
EPR1614Y against the stem cell biomarker keratin K15 lacks specificity and reacts with other keratins.
PLOS GENETICS Primary angle closure glaucoma and SPATA13
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008721 April 27, 2020 25 / 26
Sci Rep. 2019; 9(1):1943. Epub 2019/02/15. https://doi.org/10.1038/s41598-018-38163-5 PMID:
30760780; PMCID: PMC6374370.
51. Bose A, Teh MT, Hutchison IL, Wan H, Leigh IM, Waseem A. Two mechanisms regulate keratin K15
expression in keratinocytes: role of PKC/AP-1 and FOXM1 mediated signalling. PLoS One. 2012; 7(6):
e38599. Epub 2012/07/05. https://doi.org/10.1371/journal.pone.0038599 PMID: 22761689; PMCID:
PMC3384677.
52. Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS
are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol. 2010; 46
(7):536–42. Epub 2010/04/20. https://doi.org/10.1016/j.oraloncology.2010.03.022 PMID: 20400365.
53. Vishal M, Sharma A, Kaurani L, Alfano G, Mookherjee S, Narta K, et al. Genetic association and stress
mediated down-regulation in trabecular meshwork implicates MPP7 as a novel candidate gene in pri-
mary open angle glaucoma. BMC Med Genomics. 2016; 9:15. Epub 2016/03/24. https://doi.org/10.
1186/s12920-016-0177-6 PMID: 27001270; PMCID: PMC4802647.
54. Zhang Y. I-TASSER: fully automated protein structure prediction in CASP8. Proteins. 2009;77 Suppl
9:100–13. Epub 2009/09/22. https://doi.org/10.1002/prot.22588 PMID: 19768687; PMCID:
PMC2782770.
55. Plessner M, Melak M, Chinchilla P, Baarlink C, Grosse R. Nuclear F-actin formation and reorganization
upon cell spreading. J Biol Chem. 2015; 290(18):11209–16. Epub 2015/03/12. https://doi.org/10.1074/
jbc.M114.627166 PMID: 25759381; PMCID: PMC4416828.
PLOS GENETICS Primary angle closure glaucoma and SPATA13
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008721 April 27, 2020 26 / 26
